<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJNS</journal-id><journal-title-group><journal-title>World Journal of Neuroscience</journal-title></journal-title-group><issn pub-type="epub">2162-2000</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjns.2023.133011</article-id><article-id pub-id-type="publisher-id">WJNS-127177</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Evolving Profile and Determinants of Post-Stroke Cognitive Impairment in the 3rd Month among Kinshasa’s Survivors (Democratic Republic of the Congo)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ken</surname><given-names>Mwamba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Benito</surname><given-names>Kazenza</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Benjamin</surname><given-names>Longo Mbenza</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tharcisse</surname><given-names>Kayembe Kalula</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Marie-Thérèse</surname><given-names>Sombo Ayanne</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Guy</surname><given-names>Bumoko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Kinshasa School of Public Health School, University of Kinshasa, Kinshasa, Democratic Republic of the Congo</addr-line></aff><aff id="aff1"><addr-line>Departement of Neurology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo</addr-line></aff><aff id="aff3"><addr-line>Departement of Internal Medicine, Cardiology Unit, University of Kinshasa, Kinshasa, Democratic Republic of the Congo</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>07</month><year>2023</year></pub-date><volume>13</volume><issue>03</issue><fpage>160</fpage><lpage>172</lpage><history><date date-type="received"><day>14,</day>	<month>June</month>	<year>2023</year></date><date date-type="rev-recd"><day>20,</day>	<month>August</month>	<year>2023</year>	</date><date date-type="accepted"><day>23,</day>	<month>August</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Background: </b>
  Neurocognitive impairments are common among stroke survivors. Despite their negative impact on daily life, their evolving, and deter
  minants are not fully known in our context. To determine evolving charac
  teristics of post-stroke cognitive impairment in the 3rd month as well as deter
  minants among Kinshasa’s adult survivors is the aim of this study. <b>Methods:</b> We sought to determine neurocognitive deficits in the 3rd month in a prospective single-group cohort study in 3 hospital centers in Kinshasa. Eighty-six adult stroke survivors with a neurological and neuroimaging computerized diagnosis of stroke were assessed using MOCA (Montreal Cognitive Assessment) in the first and the third months post-stroke. <b>Results:</b> Neurocognitive disorders ranged from 79.1% in the first month to 54.7% in the third month after stroke (with 4.7% with severe decline). Gender female [AOR = 86.3 (CI<sub>95%</sub>: 2.8
   
  -
   
  2643.7); p
   
  &lt;
   
  0
  .
  01], Chronic hypertension ([AOR = 26.8 (CI<sub>95%</sub>: 2.55
   
  -
   
  282.55);
   
  p
   
  &lt;
   
  0
  .
  01]), the pathological lipid profile [AOR = 8.7 (CI<sub>95%</sub>: 1.10
   
  -
   
  68.82); p = 0
  .
  04] and worse MOCA score at 
  the 
  first month ([AOR = 41.2 (CI<sub>95%</sub>: 8.13
   
  -
   
  2134.81);
   
  p = 0
  .
  021]) were identified as worse predictors of cognitive impairments at the third
   
  month post-stroke. <b>Conclusion: </b>Post-stroke cognitive impairment is common and decreases in the 3rd month post-stroke. Chronic hypertension, gender, lipid profile, and the first
   
  month MOCA score are predictors of worse cognitive performance in Kinshasa survivors. These findings suggested the role of early management in improving cognition and the control of stroke risk factors.
 
</p></abstract><kwd-group><kwd>Stroke</kwd><kwd> Post Stroke Cognitive Disorders</kwd><kwd> MOCA</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Stroke is now experienced as a global pandemic. The severity of stroke is based not only on its mortality but especially on the resulting disabilities, including cognitive impairment. Post-stroke cognitive impairment defined as cognitive decline occurring 3 months after stroke due to neuroanatomical changes in cerebral strategic areas is common in stroke survivors while their underlying mechanisms are not completely elucidated [<xref ref-type="bibr" rid="scirp.127177-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.127177-ref2">2</xref>] . It is estimated that 64% of stroke survivors develop cognitive impairment [<xref ref-type="bibr" rid="scirp.127177-ref3">3</xref>] with deplorable consequences for their socio-professional future. Despite this, post-stroke cognitive disorders are underdiagnosed and underestimated in favor of motor disorders which come first in the majority of cases. Epidemiological data of PSCI are divergent, due to methodological approaches of studies. But there is, at least, an agreement on their high frequency. In Europe, particularly in Britain, the prevalence of cognitive impairment 3 months after stroke was estimated at 24% [<xref ref-type="bibr" rid="scirp.127177-ref4">4</xref>] . In Holland out of 176 subjects assessed 6 months after stroke, the prevalence of cognitive impairment was estimated at 70% [<xref ref-type="bibr" rid="scirp.127177-ref5">5</xref>] ; in Norway, 57% of survivors had developed cognitive impairment 1 year after having a stroke [<xref ref-type="bibr" rid="scirp.127177-ref6">6</xref>] . In the USA out of 212 subjects included in the Framingham study, 19.3% had developed cognitive impairment 10 years after stroke [<xref ref-type="bibr" rid="scirp.127177-ref7">7</xref>] . In Africa, in Nigeria, the CogFast study noted a prevalence of 48.3% of cognitive impairment 3 months after stroke [<xref ref-type="bibr" rid="scirp.127177-ref8">8</xref>] .</p><p>A large number of risk factors including the neuroanatomical and neuroimaging characteristics of the stroke, the pre-existing and co-existing cardiovascular risk factors as well as the clinical and demographic characteristics of the patient contribute to the pathogenesis of post-stroke cognitive impairment [<xref ref-type="bibr" rid="scirp.127177-ref9">9</xref>] . Identifying these risk factors in the acute phase and managing them where possible can help improve the cognitive profile of stroke survivors. Considering the stroke increasing incidence in low to middle-income countries including DRC, the current study aims to evaluate the neuropsychological profile of patients 3 months after their stroke as well as the determinants of cognitive disorders occurring within the same period.</p></sec><sec id="s2"><title>2. Methodology</title><sec id="s2_1"><title>2.1. Study Design and Setting</title><p>A prospective cohort study is conducted with a single group. The city of Kinshasa Province was chosen to carry out our study. This choice was motivated by the fact that Kinshasa is not only a city in full demographic growth with a consequent increase in cases of stroke in their multiple forms but also it remains to this day the only city in the DRC with advanced neuroimaging tools, including CT and Magnetic Resonance Imaging. The various hospitals including Saint Joseph Hospital, the Congolese Sino Friendship Hospital (HASC), and the Kinshasa General Reference Hospital (HGRK) were selected based on their geographical position, placing them at the crossroads of high-density municipalities and thus promoting massive accessibility for patients, including stroke patients. Indeed, this study was conducted during different study periods respectively October 2016 to June 2017, July 2017 to February 2018, and October 2017 to March 2018.</p></sec><sec id="s2_2"><title>2.2. Study Population</title><p>The study population consisted of stroke patients who met the following criteria: being adult patients aged at least 18 years old with a diagnosis of stroke documented by medical imaging, having an educational level to answer the questionnaire, not having a disability that could interfere with the progress of the assessment such as severe aphasia, paralysis, and no history of brain damage other than stroke. Patients with severe aphasia were excluded from the study.</p></sec><sec id="s2_3"><title>2.3. Sample Size</title><p>During the study period, 247 patients had been identified and certified as having had a stroke. Only eighty-six (86) were selected for our study according to the selection criteria: thirty-six (36) for Saint Joseph, thirty-seven (37) for HGRK and thirteen (13) for HASC.</p></sec><sec id="s2_4"><title>2.4. Sampling Technic</title><p>A purposive sampling was applied to select hospitals. The three hospitals were selected according to their location at the crossroads of municipalities with a high population density. The Saint Joseph Hospital located on Boulevard Lumumba is an access point for the inhabitants of the communes of Limete, Lemba, and Kingabwa. The HGRK is the affluent point of the inhabitants of the communes of Kinshasa, Lingwala, Gombe and even Barumbu. The HASC receives the inhabitants of the N’Djili, Masina, and Kimbanseke communes.</p></sec><sec id="s2_5"><title>2.5. Data Collection</title><p>Interviews with a structured questionnaire were used to collect data from the patients selected. Training sessions were organized for interviewers recruited by the investigator. These sessions covered the objectives of the study, variables of interest, the methodology of the study, and the pilot checking tool’s consistency. The questionnaire covered all sociodemographic, clinical, and paraclinical information and neuropsychological characteristics. For data collection, four interviewers were recruited to ensure data collection. All data were sent to the investigator for checking and feedback for improvements.</p></sec><sec id="s2_6"><title>2.6. Variables of Interest</title><p>Socio-demographic characteristics such as age, sex, education, and occupation were collected. Level of education was defined as the highest level of education attained by the patient. Occupation was assessed by seeking the exercise of a public or private professional activity. Those with no activity were classified as non-active subjects and those with occupational activity were classified as active patients.</p><p>Clinically, the patient’s state of consciousness was measured. Consciousness was retained when the patient or caregiver did not report altered consciousness during the stroke; It is said to be impaired when the patient reported a disturbance of consciousness at the time of stroke either in a coma situation or in confusion. In addition, a history of high blood pressure, diabetes mellitus, alcohol, and tobacco were sought. Neuroradiological data: took into account the type of stroke, hemispheric and corticosteroid or subcortical location, vascular territory, and lesions associated with stroke.</p><p>Cognitive functions were explored by the MOCA version 7.1 or Montreal Cognitive Assessment. This test was designed with the main objective of screening for mild neurocognitive impairment. It is a short-answer questionnaire that lasts 5 to 10 minutes. The elements assessed are grouped into 6 subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, and temporospatial orientation. The maximum score is 30 points. Patients were grouped into 5 classes: pathological (&lt;26), normal (26 - 30), mild cognitive impairment (18 - 25), moderate cognitive impairment (10 - 17) and severe cognitive impairment (&lt;10). A correction was made according to the level of education, it is necessary to add a point if the patient’s schooling is 12 years or less [<xref ref-type="bibr" rid="scirp.127177-ref10">10</xref>] .</p></sec><sec id="s2_7"><title>2.7. Exposure and Outcome</title><p>In this study, stroke was considered the exposure. Its measurement was made based on the patient’s clinical picture and the cerebroscannographic confirmation. Impairment of cognitive function assessed by MOCA was the main variable of interest.</p></sec><sec id="s2_8"><title>2.8. Follow-Up</title><p>As the cohort was open-label, each stroke patient was followed for a period of 3 months. Patients were identified as soon as they were admitted to the emergency department. Consent to participate in the study was obtained either from the accompanying person or from the patient himself. The first neurocognitive assessment was performed within the first 30 days after the stroke and the second assessment at month three post-stroke using MOCA. Tests were performed by appointment either in a hospital or at home. Potential confounders such as age, gender, socioeconomic level, occupation, and educational attainment were measured.</p><p>A total of 86 adults with a diagnosis of stroke had to fulfill the neurological and neuroimaging criteria for the disease and were subjected to neuropsychological testing using the MOCA for cognition in the first month following the stroke. All risk factors of cognitive decline were collected. After baseline information was collected, subjects in a prospective cohort study approach were then followed longitudinally, in the third month after the stroke. All study participants fulfilled the following inclusion criteria: post-stroke adult with a computerized diagnosis, education level that enables him to answer the questionnaire, no carrier of a disability that should interfere with the progress of the assessment such as severe aphasia or paralysis, and no history of brain damage other than stroke.</p></sec><sec id="s2_9"><title>2.9. Statistical Analysis</title><p>Data were collected and coded according to the categories whether they were open-ended or closed-ended questions. Encoded and unencoded data was entered on the computer using Microsoft Excel. After quality control, the data were transferred to the SPSS software version 20.0 for various analyses. The proportions were used to determine the extent of cognitive impairment in the stroke patient.</p><p>The quantitative variables were summarized on average and the standard deviation. Proportion was used to summarize qualitative variables. The Z-test for the difference in proportions; the Student-test for the comparison of means; and the chi-square to look for the association between cognitive function disorders and the different risk factors for cognitive disorders. Relative risk was calculated to confirm associations. Results were considered significant when p was ≤ 0.05.</p></sec><sec id="s2_10"><title>2.10. Ethics</title><p>The proposal received ethical approval from the ethics committees of the Kinshasa School of Public Health (ESP/CE/01B/2018). Participation was voluntary. All participants provided written informed consent after a full explanation of the nature, purpose, and procedures used in the study. The participants were informed that responses would be anonymous and that they were free to withdraw from the interview or discussion at any time.</p></sec></sec><sec id="s3"><title>3. Results</title><p>A total of 86 patients were selected for our study. The average age was 58.5 (49 - 67), the male gender was more representative, sociodemographic, and para-clinical variables had been searched (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Indeed, three-quarters of patients had an occupation (76.7%) and nearly nine out of ten patients had at least 7 years of study (91.9). With regard to clinical and para-clinical history, <xref ref-type="table" rid="table1">Table 1</xref> shows that at least one patient in five had smoked in the past (18.6%), and nearly seven patients had a history of alcohol intake (69.8%). In addition, at the time of admission to the emergency room, at least five out of ten patients had chronic hypertension (54.7%), and nearly six out of ten diseases had an altered state of consciousness (61.6%Ischemic stroke was the most common form (70.9%). Finally, the analysis of CT images of stroke patients revealed that the subcortical region was the most affected (66.3%). The left hemispheric localization was the most encountered (72.1%) and involvement of the basivertebral territory was found in one patient in five (20.6%).</p><p>The study showed that cognitive disorders in survivors were observed in 79.1% of cases in the 1st month after stroke, and their proportions were reduced</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Sociodemographic and clinical characteristics of stroke survivors</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >N(%)</th></tr></thead><tr><td align="center" valign="middle" >Age (Median/P35-P75)</td><td align="center" valign="middle" >58.5 (49 - 67)</td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >59 (68.6)</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >27 (31.4)</td></tr><tr><td align="center" valign="middle" >Occupation</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Active</td><td align="center" valign="middle" >66 (76.7)</td></tr><tr><td align="center" valign="middle" >Not-active</td><td align="center" valign="middle" >20 (23.3)</td></tr><tr><td align="center" valign="middle" >Level of study</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤7</td><td align="center" valign="middle" >7 (8.1)</td></tr><tr><td align="center" valign="middle" >&gt;7</td><td align="center" valign="middle" >79 (91.9)</td></tr><tr><td align="center" valign="middle" >Tobacco</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >16 (18.6)</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >70 (81.4)</td></tr><tr><td align="center" valign="middle" >Alcohol</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >60 (69.8)</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >26 (30.2)</td></tr><tr><td align="center" valign="middle" >Type alcohol consumption</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Not excessive</td><td align="center" valign="middle" >36 (60)</td></tr><tr><td align="center" valign="middle" >Excessive</td><td align="center" valign="middle" >24 (40)</td></tr><tr><td align="center" valign="middle" >Chronic hypertension</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >47 (54.7)</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >39 (45.3)</td></tr><tr><td align="center" valign="middle" >State of consciousness</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Preserved</td><td align="center" valign="middle" >53 (61.6)</td></tr><tr><td align="center" valign="middle" >Disturbed</td><td align="center" valign="middle" >33 (38.4)</td></tr><tr><td align="center" valign="middle" >Stroke type</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ischemic</td><td align="center" valign="middle" >61 (70.9)</td></tr><tr><td align="center" valign="middle" >Hemorrhagic</td><td align="center" valign="middle" >25 (29.1)</td></tr><tr><td align="center" valign="middle" >Region</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cortical</td><td align="center" valign="middle" >29 (33.7)</td></tr><tr><td align="center" valign="middle" >Sub-cortical</td><td align="center" valign="middle" >57 (66.3)</td></tr><tr><td align="center" valign="middle" >Localization</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Left hemispheric</td><td align="center" valign="middle" >62 (72.1)</td></tr><tr><td align="center" valign="middle" >Right hemispheric</td><td align="center" valign="middle" >21 (24.4)</td></tr><tr><td align="center" valign="middle" >Bi-hemispheric</td><td align="center" valign="middle" >3 (3.5)</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >Vascular territory</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Carotid</td><td align="center" valign="middle" >68 (79.1)</td></tr><tr><td align="center" valign="middle" >Basilar vertebro</td><td align="center" valign="middle" >18 (20.9)</td></tr><tr><td align="center" valign="middle" >Lipid profil</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pathological</td><td align="center" valign="middle" >44 (51.2)</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >42 (48.8)</td></tr></tbody></table></table-wrap></table-wrap-group><p>3 months later to 54.7% (<xref ref-type="table" rid="table2">Table 2</xref>). The severity of cognitive impairment decreased from 16.3% to 4.7% from the 1st to 3rd month after stroke (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>Furthermore, <xref ref-type="table" rid="table4">Table 4</xref> summarizes the analysis of the homogeneity of explanatory variables in patient groups. It shows that the distribution of explanatory variables such as age, sex, and schooling was not homogeneous in the two groups (p &gt; 0.05). On the other hand, only chronic hypertension, alcohol consumption, and MOCA impairment in the first month at admission were homogeneously distributed in both groups (p &lt; 0.01) (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>PSCI predictors are shown in <xref ref-type="table" rid="table5">Table 5</xref>. Female patients and patients with chronic hypertension had respectively 86 times (ORA = 86.3; IC 2.8 - 2643.7; p = 0.01) and 36 times (ORA = 26.8; CI<sub>95%</sub> 2.55 - 282.55; p &lt; 0.01) at risk of developing PSCI. Patients with pathological lipid profile and pathological MOCA in the first month were respectively 8 times (ORA = 8.7; CI<sub>95%</sub> 1.10 - 68.82; p &lt; 0.01) and 41 times (ORA = 41.2; CI<sub>95%</sub> 8.13 - 2134.8; p = 0.021) more exposed to PSCI (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>This study presented an evaluation of cognitive performance using MOCA among post-stroke survivors in the first and third months after stroke. Our results showed that post-stroke cognitive impairment was common in many survivors, especially in the first moments after stroke, with proportions of impaired patients varying from 79.1% in the first month to 54.7% in the third month after stroke, as reported by Rasquin et al. during the same period [<xref ref-type="bibr" rid="scirp.127177-ref5">5</xref>] . This high prevalence is due, on the one hand to the acute neuroanatomic lesions underlying the stroke, including cerebral hypoperfusion, cytotoxic and vasogenic edema, brain neurotransmission disturbances, hyperglycemia, and neuroinflammation, and on the other to patient pre-existing specific factors, including (age, high blood pressure, diabetic…). Three months after the stroke, cognitive disorders decreased from 79.1% to 54.7% slightly higher than the findings of some authors among which Akinyemi et al. [<xref ref-type="bibr" rid="scirp.127177-ref8">8</xref>] and Tu et al. [<xref ref-type="bibr" rid="scirp.127177-ref11">11</xref>] but lower than Yu et al. [<xref ref-type="bibr" rid="scirp.127177-ref12">12</xref>] . This decrease in PSCI is probably related to the effects of early management or functionally dynamic factors in the acute phase of the stroke mentioned above.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Evolving of PSCI from the 1st month and to the 3rd month after stroke</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Period</th><th align="center" valign="middle" >%</th></tr></thead><tr><td align="center" valign="middle" >1st month</td><td align="center" valign="middle" >79.1</td></tr><tr><td align="center" valign="middle" >3rd month</td><td align="center" valign="middle" >54.7</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Proportion (%) of cognitive impairment</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Evolving cognitive impairment severity from the 1st to the 3rd month after stroke</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Type of Cognitive Impairment</th><th align="center" valign="middle" >1st Month</th><th align="center" valign="middle" >3rd Month</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Mild</td><td align="center" valign="middle" >37.2</td><td align="center" valign="middle" >38.4</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Moderate</td><td align="center" valign="middle" >25.6</td><td align="center" valign="middle" >11.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Severe</td><td align="center" valign="middle" >16.3</td><td align="center" valign="middle" >4.7</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="4"  >Proportion (%) of cognitive impairment</td></tr></tbody></table></table-wrap><table-wrap-group id="4"><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Differences in clinical neuroimaging and neuropsychological characteristics of stroke survivors with and without cognitive impairment</title></caption><table-wrap id="4_1"><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >MOCA Impairment</th><th align="center" valign="middle" >Normal MOCA</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Age (M &#177; SD)</td><td align="center" valign="middle" >60.4 &#177; 10.6</td><td align="center" valign="middle" >56.4 &#177; 11.8</td><td align="center" valign="middle" >0.103</td></tr><tr><td align="center" valign="middle" >MOCA (M &#177; SD)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >1st month</td><td align="center" valign="middle" >12.4 &#177; 6.9</td><td align="center" valign="middle" >24.4 &#177; 3.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3rd month</td><td align="center" valign="middle" >19.09 &#177; 6.5</td><td align="center" valign="middle" >27.9 &#177; 1.3</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >33 (55.9)</td><td align="center" valign="middle" >26 (26.8)</td><td align="center" valign="middle" >0.724</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >14 (51.9)</td><td align="center" valign="middle" >13 (48.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Occupation status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.292</td></tr><tr><td align="center" valign="middle" >Active</td><td align="center" valign="middle" >34 (51.5)</td><td align="center" valign="middle" >32 (48.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Not-active</td><td align="center" valign="middle" >13 (65.0)</td><td align="center" valign="middle" >7 (35.0)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Level of study</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.762</td></tr><tr><td align="center" valign="middle" >≤7</td><td align="center" valign="middle" >3 (42.9)</td><td align="center" valign="middle" >4 (57.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;7</td><td align="center" valign="middle" >44 (55.7)</td><td align="center" valign="middle" >35 (44.3)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Tobacco</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >37 (52.9)</td><td align="center" valign="middle" >33 (47.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >10 (62.5)</td><td align="center" valign="middle" >6 (37.5)</td><td align="center" valign="middle" >0.486</td></tr><tr><td align="center" valign="middle" >Alcohol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >34 (56.7)</td><td align="center" valign="middle" >26 (43.3)</td><td align="center" valign="middle" >0.568</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >13 (50.0)</td><td align="center" valign="middle" >13 (50.0)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Alcohol consumption</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.03</td></tr><tr><td align="center" valign="middle" >Not excessive</td><td align="center" valign="middle" >16 (44.4)</td><td align="center" valign="middle" >20 (55.6)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Excessive</td><td align="center" valign="middle" >18 (75.0)</td><td align="center" valign="middle" >6 (25.0)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="4_2"><table><tbody><thead><tr><th align="center" valign="middle" >Chronic hypertension</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >40 (85.1)</td><td align="center" valign="middle" >7 (14.9)</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >23 (58.9)</td><td align="center" valign="middle" >16 (41.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >State of consciousness</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.077</td></tr><tr><td align="center" valign="middle" >Preserved</td><td align="center" valign="middle" >25 (47.2)</td><td align="center" valign="middle" >28 (52.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Disturbed</td><td align="center" valign="middle" >22 (66.7)</td><td align="center" valign="middle" >11 (33.3)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Stroke type</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.111</td></tr><tr><td align="center" valign="middle" >Ischemic</td><td align="center" valign="middle" >30 (49.2)</td><td align="center" valign="middle" >31 (50.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hemorrhagic</td><td align="center" valign="middle" >17 (68.0)</td><td align="center" valign="middle" >8 (32.0)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Region</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.697</td></tr><tr><td align="center" valign="middle" >Cortical</td><td align="center" valign="middle" >15 (51.7)</td><td align="center" valign="middle" >14 (48.3)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Sub-corticale</td><td align="center" valign="middle" >32 (56.1)</td><td align="center" valign="middle" >25 (43.9)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Localization</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.999</td></tr><tr><td align="center" valign="middle" >Left hemisphere</td><td align="center" valign="middle" >32 (51.6)</td><td align="center" valign="middle" >30 (48.4)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Right hemisphere</td><td align="center" valign="middle" >13 (61.9)</td><td align="center" valign="middle" >8 (38.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Bi-hemisphere</td><td align="center" valign="middle" >2 (66.7)</td><td align="center" valign="middle" >1 (33.3)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Vascular territory</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.249</td></tr><tr><td align="center" valign="middle" >Carotid</td><td align="center" valign="middle" >35 (51.5)</td><td align="center" valign="middle" >33 (48.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Basilar vertebro</td><td align="center" valign="middle" >12 (66.7)</td><td align="center" valign="middle" >6 (33.3)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Lipid profil</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.087</td></tr><tr><td align="center" valign="middle" >Impaired</td><td align="center" valign="middle" >28 (63.6)</td><td align="center" valign="middle" >16 (36.4)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >19 (45.2)</td><td align="center" valign="middle" >23 (54.8)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MOCA in the first month</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Impaired</td><td align="center" valign="middle" >47 (69.1)</td><td align="center" valign="middle" >21 (30.9)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >1 (5.5)</td><td align="center" valign="middle" >17 (94.5)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><table-wrap-group id="5"><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Clinical, neuroimaging and neuropsychological predictors of PSCI</title></caption><table-wrap id="5_1"><table><tbody><thead><tr><th align="center" valign="middle" >Characteristics</th><th align="center" valign="middle" >MOCA Impaired</th><th align="center" valign="middle" >Normal MOCA</th><th align="center" valign="middle" >COR</th><th align="center" valign="middle" >CI<sub>95%</sub></th><th align="center" valign="middle" >AOR</th><th align="center" valign="middle" >CI<sub>95%</sub></th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Age (M &#177; SD)</td><td align="center" valign="middle" >60.4 &#177; 10.6</td><td align="center" valign="middle" >56.4 &#177; 11.8</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MOCA (M &#177; SD)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1st month</td><td align="center" valign="middle" >12.4 &#177; 6.9</td><td align="center" valign="middle" >24.4 &#177; 3.6</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3rd month</td><td align="center" valign="middle" >19.09 &#177; 6.5</td><td align="center" valign="middle" >27.9 &#177; 1.3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >33 (55.9)</td><td align="center" valign="middle" >26 (26.8)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >14 (51.9)</td><td align="center" valign="middle" >13 (48.1)</td><td align="center" valign="middle" >0.85</td><td align="center" valign="middle" >[0.34 - 2.11]</td><td align="center" valign="middle" >86.3</td><td align="center" valign="middle" >[2.8 - 2643.7]</td><td align="center" valign="middle" >0.01*</td></tr><tr><td align="center" valign="middle" >Occupation status</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Active</td><td align="center" valign="middle" >34 (51.5)</td><td align="center" valign="middle" >32 (48.5)</td><td align="center" valign="middle" >1.75</td><td align="center" valign="middle" >[0.62 - 4.94]</td><td align="center" valign="middle" >4.03</td><td align="center" valign="middle" >[0.31 - 52.95]</td><td align="center" valign="middle" >0.288</td></tr><tr><td align="center" valign="middle" >No-active</td><td align="center" valign="middle" >13 (65.0)</td><td align="center" valign="middle" >7 (35.0)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="5_2"><table><tbody><thead><tr><th align="center" valign="middle" >Level of study</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >≤ 7 years</td><td align="center" valign="middle" >3 (42.9)</td><td align="center" valign="middle" >4 (57.1)</td><td align="center" valign="middle" >0.59</td><td align="center" valign="middle" >[0.12 - 2.84]</td><td align="center" valign="middle" >0.53</td><td align="center" valign="middle" >[0.09 - 3.04]</td><td align="center" valign="middle" >0.484</td></tr><tr><td align="center" valign="middle" >&gt;7 years</td><td align="center" valign="middle" >44 (55.7)</td><td align="center" valign="middle" >35 (44.3)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Tobacco consumption</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >10 (62.5)</td><td align="center" valign="middle" >6 (375)</td><td align="center" valign="middle" >1.49</td><td align="center" valign="middle" >[0.49 - 4.53]</td><td align="center" valign="middle" >1.21</td><td align="center" valign="middle" >[0.07 - 19.02]</td><td align="center" valign="middle" >0.891</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >37 (52.9)</td><td align="center" valign="middle" >33 (47.1)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Type alcohol consumption</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >34 (56.7)</td><td align="center" valign="middle" >26 (43.3)</td><td align="center" valign="middle" >3.98</td><td align="center" valign="middle" >[1.42 - 11.08]</td><td align="center" valign="middle" >4.2</td><td align="center" valign="middle" >[0.46 - 38.17]</td><td align="center" valign="middle" >0.202</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >13 (50.0)</td><td align="center" valign="middle" >13 (50.0)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Chronic hypertension</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >40 (85.1)</td><td align="center" valign="middle" >7 (14.9)</td><td align="center" valign="middle" >3.9</td><td align="center" valign="middle" >[1.42 - 11.57]</td><td align="center" valign="middle" >26.8</td><td align="center" valign="middle" >[2.55 - 282.55]</td><td align="center" valign="middle" >0.006*</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >23 (58.9)</td><td align="center" valign="middle" >16 (41.1)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >State of consciousness</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Preserved</td><td align="center" valign="middle" >22 (66.7)</td><td align="center" valign="middle" >11 (33.3)</td><td align="center" valign="middle" >2.24</td><td align="center" valign="middle" >[0.91 - 5.52]</td><td align="center" valign="middle" >0.62</td><td align="center" valign="middle" >[0.07 - 5.26]</td><td align="center" valign="middle" >0.667</td></tr><tr><td align="center" valign="middle" >Disturbed</td><td align="center" valign="middle" >25 (47.2)</td><td align="center" valign="middle" >28 (52.8)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Stroke type</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hemorrhagic</td><td align="center" valign="middle" >17 (68.0)</td><td align="center" valign="middle" >8 (32.0)</td><td align="center" valign="middle" >2.19</td><td align="center" valign="middle" >[0.82 - 5.84]</td><td align="center" valign="middle" >7.6</td><td align="center" valign="middle" >[0.58 - 98.24]</td><td align="center" valign="middle" >0.120</td></tr><tr><td align="center" valign="middle" >Ischemical</td><td align="center" valign="middle" >30 (49.2)</td><td align="center" valign="middle" >31 (50.8)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Region</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Sub-cortical</td><td align="center" valign="middle" >32 (56.1)</td><td align="center" valign="middle" >25 (43.9)</td><td align="center" valign="middle" >1.19</td><td align="center" valign="middle" >[0.48 - 2.98]</td><td align="center" valign="middle" >5.3</td><td align="center" valign="middle" >[0.53 - 53.86]</td><td align="center" valign="middle" >0.155</td></tr><tr><td align="center" valign="middle" >Cortical</td><td align="center" valign="middle" >15 (51.7)</td><td align="center" valign="middle" >14 (48.3)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Vascular territory</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Carotid</td><td align="center" valign="middle" >35 (51.5)</td><td align="center" valign="middle" >33 (48.5)</td><td align="center" valign="middle" >1.19</td><td align="center" valign="middle" >[0.48 - 2.92]</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >[0.28 - 139.88]</td><td align="center" valign="middle" >0.247</td></tr><tr><td align="center" valign="middle" >Basilar vertebral</td><td align="center" valign="middle" >12 (66.7)</td><td align="center" valign="middle" >6 (33.3)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Lipide profile</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pathological</td><td align="center" valign="middle" >28 (63.6)</td><td align="center" valign="middle" >16 (36.4)</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >[0.89 - 5.02]</td><td align="center" valign="middle" >8.7</td><td align="center" valign="middle" >[1.10 - 68.82]</td><td align="center" valign="middle" >0.040*</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >19 (45.2)</td><td align="center" valign="middle" >23 (54.8)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MOCA at the first month</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Pathological</td><td align="center" valign="middle" >47 (69.1)</td><td align="center" valign="middle" >21 (30.9)</td><td align="center" valign="middle" >36.5</td><td align="center" valign="middle" >[6.02 - 817.8]</td><td align="center" valign="middle" >41.2</td><td align="center" valign="middle" >[8.13 - 2134.8]</td><td align="center" valign="middle" >0.021*</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >1 (5.5)</td><td align="center" valign="middle" >17 (94.5)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>Our study confirms previous reports that female status is associated with PSCI [<xref ref-type="bibr" rid="scirp.127177-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.127177-ref14">14</xref>] . It should be noted that in many countries around the world women’s literacy is not yet universally accepted, in sub-African countries where women have difficulty accessing higher education. This implies a fairly limited cognitive reserve [<xref ref-type="bibr" rid="scirp.127177-ref15">15</xref>] which easily exposes them to cognitive decline in the face of a major brain attack such as a stroke.</p><p>As Jacquin et al. and Salvadori E et al. [<xref ref-type="bibr" rid="scirp.127177-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.127177-ref16">16</xref>] our study confirms that a poor MOCA score in the first month is one of the strongest predictors of PSCI in the 3rd month.</p><p>High blood pressure and cognitive function have long been the subject of several controversies. Seux et al. [<xref ref-type="bibr" rid="scirp.127177-ref17">17</xref>] highlighted the negative impact of chronic hypertension on intellectual abilities in a review. This impact may occur through micros infarctions or damage to white matter caused by hypertension. Our study showed a significant association between hypertension and poorer cognitive performance. As the most common risk factor for stroke, hypertension is associated with an increased risk of stroke and by extension stroke-related cognitive impairments. In addition to the severity of increased blood pressure, the duration of the hypertensive state would be an important determinant of cognitive impairment through micros infarctions or damage to white matter [<xref ref-type="bibr" rid="scirp.127177-ref18">18</xref>] . High serum LDL and Triglyceride levels were identified as cognitive impairment predictors in the 3rd month post-stroke, as reported in several studies [<xref ref-type="bibr" rid="scirp.127177-ref19">19</xref>] . The risk of cognitive disorders after acute ischemic stroke increases with increased cholesterol levels. Dyslipidemia is not only an independent and maybe the most important risk factor for ischemic stroke, which tends to cause hidden, progressive, and somatic organic damage, but also affects the cognitive function of patients with ischemic stroke through accelerating systemic atherosclerosis, and it is believed to be a risk factor inducing cognitive disorders, even dementia [<xref ref-type="bibr" rid="scirp.127177-ref20">20</xref>] . This study had some limitations, including not being able to specify in great detail the previous cognitive status of stroke survivors. Our sample was also small because of financial difficulties that did not allow us to perform all the examinations, especially those of an inflammatory nature (cytokines, CRP...) that could also justify post-stroke cognitive disorders.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In addition to the burden of the stroke itself, many burdens of stroke is due to its complications, including cognitive impairments. Cognitive disorders due to their high frequency, severity, and consequences should be sought as well as associated with stroke at the first moment to manage them early at best to prevent them.</p></sec><sec id="s6"><title>Ethical Approval and Consent to Participate</title><p>Ethical clearance was obtained from the Ethics Committees of the Kinshasa School of Public Health (reference number: ESP/CE/01B/2018). Consent was obtained from each respondent during data collection. Privacy and confidentiality were maintained throughout the study.</p></sec><sec id="s7"><title>Availability of Data and Materials</title><p>All data and supporting documents for this study are available at the Department of Neurology, University of Kinshasa. They will be made available upon request to the leading author.</p></sec><sec id="s8"><title>Authors’ Contribution</title><p>Ken Mwamba designed the study, collected data, written and submitted a manuscript. Benito Kazenza wrote the statistical plane, cleaned, and analyzed the data. Benjamin Longo Mbenza reviewed and approved the manuscript. Tharcisse Kayembe Kalula reviewed and approved the manuscript. Marie Th&#233;r&#232;se Sombo Ayanne reviewed and approved the manuscript. Guy Bumoko designed the study, supervised data collection, and reviewed, and approved the manuscript.</p></sec><sec id="s9"><title>Acknowledgements</title><p>The authors acknowledge the Department of Neurology of the University of Kinshasa for permission granted and three Hospitals of Kinshasa where we collected data.</p></sec><sec id="s10"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></sec><sec id="s11"><title>Cite this paper</title><p>Mwamba, K., Kazenza, B., Mbenza, B.L., Kalula, T.K., Ayanne, M.T.S. and Bumoko, G. (2023) Evolving Profile and Determinants of Post-Stroke Cognitive Impairment in the 3rd Month among Kinshasa’s Survivors (Democratic Republic of the Congo). World Journal of Neuroscience, 13, 160-172. https://doi.org/10.4236/wjns.2023.133011</p></sec></body><back><ref-list><title>References</title><ref id="scirp.127177-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jacquin, A., Binquet, C., Rouaud, O., Graule-Petot, A., Daubail, B., Osseby, G.V., et al. (2014) Post Stroke Cognitive Impairment: High Prevalence and Determining Factors in a Cohort of Mild Stroke. Journal of Alzheimer’s Disease, 40, 1029-1038.  
https://doi.org/10.3233/JAD-131580</mixed-citation></ref><ref id="scirp.127177-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Washida, K., Kowa, H., Hamaguchi, H., Tachibana, H., Sekiguchi, H., et al. (2015) Clinical Features Diagnosis and Treatment of Post Stroke Cognitive Impairment. Austin Journal of Clinical Neurology, 2, Article 1031.</mixed-citation></ref><ref id="scirp.127177-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jin, Y.P., Di Legge, S., Ostbye, T., Feightner, J.W. and Hachinski, V. (2006) The Reciprocal Risks of Stroke and Cognitive Impairment in an Elderly Population. Alzheimer’s &amp; Dementia, 2, 171-178. https://doi.org/10.1016/j.jalz.2006.03.006</mixed-citation></ref><ref id="scirp.127177-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Douiri, A., Rudd, A.G. and Wolfe, C.D. (2013) Prevalence of Post Stroke Cognitive Impairment: South London Stroke Register 1995-2010. Stroke, 44, 138-145.  
https://doi.org/10.1161/STROKEAHA.112.670844</mixed-citation></ref><ref id="scirp.127177-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rasquin, S.M., Verhey, F.R., Van Oostenbrugge, R.J., Lousberg, R. and Lodder, J. (2004) Demographic and CT Scan Features Related to Cognitive Impairement in the First Year after Stroke. Journal of Neurology, Neurosurgery &amp; Psychiatry, 75, 1562-1567. https://doi.org/10.1136/jnnp.2003.024190</mixed-citation></ref><ref id="scirp.127177-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ihle-Hansen, H., Thommessen, B., Wyller, T.B., et al. (2011) Incidence and Subtypes of MCI and Dementia 1 Year after First-Ever Stroke in Patients without Pre-Existing Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 32, 401-407.  
https://doi.org/10.1159/000335361</mixed-citation></ref><ref id="scirp.127177-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ivan, C.S., Seshadri, S., Beiser, A., et al. (2004) Dementia after Stroke: The Framingham Study. Stroke, 35, 1264-1268.  
https://doi.org/10.1161/01.STR.0000127810.92616.78</mixed-citation></ref><ref id="scirp.127177-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Akinyemi, R.O., Allan, L., Owolabi, M.O., Akinyemi, J.O., Ogbole, G., Ajani, A., Firbank, M., Ogunniyi, A. and Kalaria, R.N. (2014) Profile and Determinants of Vascular Cognitive Impairment in African Stroke Survivors: The Cog Fast Nigeria Study. Journal of the Neurological Sciences, 346, 241-249.  
https://doi.org/10.1016/j.jns.2014.08.042</mixed-citation></ref><ref id="scirp.127177-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Danovska, M., Stamenov, B., Alexandrova, M. and Peychinska, D. (2012) Post Stoke Cognitive Impairment—Phenomenology and Pronostics Factors. Journal of IMAB-Annual Proceeding, 18, 290-297. https://doi.org/10.5272/jimab.2012183.290</mixed-citation></ref><ref id="scirp.127177-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nasreddine, Z.S., Phillips, N.A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Chertkow, H., et al. (2005) The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool for Mild Cognitive Impairment. Journal of the American Geriatrics Society, 53, 695-699https://doi.org/10.1111/j.1532-5415.2005.53221.x</mixed-citation></ref><ref id="scirp.127177-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Tu, Q., Ding, B., Yang, X., et al. (2014) The Current Situation on Vascular Cognitive Impairment after Ischemic Stroke in Changsha. Archives of Gerontology and Geriatrics, 58, 236-247. https://doi.org/10.1016/j.archger.2013.09.006</mixed-citation></ref><ref id="scirp.127177-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yu, K.H., Cho, S.J., Oh, M.S., Jung, S., Lee, J.H., Shin, J.H., Koh, I.S., Cha, J.K., Park, J.M., Bae, H.J., Kang, Y. and Lee, B.C. (2013) Korean-Vascular Cognitive Impairment Harmonization Standards in a Multicenter Prospective Stroke Cohort in Korea. Stroke, 44, 786-788. https://doi.org/10.1161/STROKEAHA.112.668343</mixed-citation></ref><ref id="scirp.127177-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X.L., et al. (2016) Predictors for Vascular Cognitive Impairment in Stroke Patients. BMC Neurology, 16, Article No. 115.  
https://doi.org/10.1186/s12883-016-0638-8</mixed-citation></ref><ref id="scirp.127177-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mapoure, Y.N., et al. (2017) Post Stroke Cognitive Impairment in Douala (Cameroon). African Journal of Neurological Sciences, 36, 43-52.</mixed-citation></ref><ref id="scirp.127177-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Delecraz, J. (2016) Reserve Cognitive: Qu’est-ce que c’est, qu’elle relation a-t-elle avec le vieillissement cérébral et la maladie d’Alzheimer et comment l’augmenter? Cognitif Santé, Cerveau Neurosciences, Nov 30.  
https://yourbrain.health/fr/reserve-cognitive/</mixed-citation></ref><ref id="scirp.127177-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Salvadori, E., Passi, M., Poggesi, A., Chili, G., Inzitari, D., Pantoni, L., et al. (2013) Predictive Value of MOCA in the Acute Phase of Stroke on the Diagnosis Mid-Term Cognitive Impairment. Journal of Neurology, 260, 2220-2227.  
https://doi.org/10.1007/s00415-013-6962-7</mixed-citation></ref><ref id="scirp.127177-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Seux, M.L. and Forette, F. (1999) Effects of Hypertension and Its Treatment on Mental Function. Current Hypertension Report, 1, 232-237. 
https://doi.org/10.1007/s11906-999-0026-5</mixed-citation></ref><ref id="scirp.127177-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kalaria, R.N., Akinyemi, R. and Ihara, M. (2016) Stroke Injury, Cognitive Impairment and Vascular Dementia. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1862, 915-925.  
https://doi.org/10.1016/j.bbadis.2016.01.015</mixed-citation></ref><ref id="scirp.127177-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Anstey, K.J., Lipnicki, D.M. and Low, L.F. (2008) Cholesterol as a Risk Factor for Dementia and Cognitive Decline: A Systematic Review of Prospective Studies with Mate-Analysis. The American Journal of Geriatric Psychiatry, 16, 343-354.  
https://doi.org/10.1097/01.JGP.0000310778.20870.ae</mixed-citation></ref><ref id="scirp.127177-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zou, Y., Zhu, Q., Deng, Y., Duan, J., Pan, L., Tu, Q., et al. (2014) Vascular Risk Factors and Mild Cognitive Impairment in the Elderly Population in Southwest China. American Journal of Alzheimer’s Disease &amp; Other Dementias, 29, 242-247.  
https://doi.org/10.1177/1533317513517042</mixed-citation></ref></ref-list></back></article>